Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02406144
Other study ID # GEM2014MAIN
Secondary ID
Status Completed
Phase Phase 3
First received March 25, 2015
Last updated November 28, 2017
Start date November 2014
Est. completion date November 2017

Study information

Verified date November 2017
Source PETHEMA Foundation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This protocol is a randomized, open-label, national, multicenter trial studying maintenance treatment with lenalidomide and dexamethasone versus lenalidomide, dexamethasone and MLN9708 after autologous hematopoietic stem cell transplantation in patients with newly-diagnosed symptomatic multiple myeloma.

A total of 316 patients, from the study GEM2012MENOS65, will be enrolled in the study.

The pre-treatment period includes the screening visit in which participants provide informed consent in writing in order to take part in the study. The patient is then assessed to determine his/her eligibility. The selection process will begin 21 days before the first dose of medication is administered (days -21 to 0). All procedures during the pre-treatment period will be carried out after completion of the two cycles of post-transplant consolidation with VRD which coincide with the end-of-study visit of clinical trial GEM2012MENOS65.

During the treatment period, eligible patients will be included in the study and receive maintenance treatment with lenalidomide/dexamethasone versus lenalidomide/dexamethasone/MLN9708. Each cycle will last 28 days. Treatment arm A will consist of oral administration of 15 mg/day of oral lenalidomide on days 1-21, and 20 mg/day of dexamethasone administered orally on days 1-4 and 9-12 for a period of two years. Arm B of the maintenance treatment will be the same as arm A, with the addition of MLN9708 during the two year maintenance period, at a dose of 4 mg/day on days 1, 8 and 15 of the cycle.

At two years, patients with negative MRD will finish maintenance treatment. Patients with positive MRD will continue treatment with lenalidomide/dexamethasone until they have completed five years of maintenance treatment. In this case, 20 mg/day of dexamethasone will only be administered on days 1-4 of the cycle. The dose of lenalidomide will not be adjusted. (unless necessary to treat adverse events)

Once this phase of active treatment is complete, patients will begin the long-term follow-up phase, during which they will be visited every three months to evaluate progression and survival.


Description:

The primary trial objectives are:

• Impact on progression-free survival (PFS) when adding MLN9708 to post-transplant maintenance treatment with lenalidomide/dexamethasone in patients with multiple myeloma.

The secondary trial objectives are:

- Evaluate development and clinical significance of minimal residual disease (MRD) from the time maintenance treatment is initiated, yearly over five years.

- Overall survival (OS).

- Evaluate the safety and tolerability of the maintenance treatment.


Recruitment information / eligibility

Status Completed
Enrollment 316
Est. completion date November 2017
Est. primary completion date September 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 67 Years
Eligibility Inclusion Criteria:

- The patient must, in the opinion of the investigator, be capable of complying with all requirements of the trial.

- Have signed the informed consent form

- Be between 18 and 67 years of age

- Have an ECOG Performance Status <= 2 (or 3 if the ECOG is due to myeloma, e.g. pathological fracture)

- Multiple myeloma patient who was included in the GEM2012MENOS65 trial, and who is found to have, at a minimum, minimal response after consolidation

- Life expectancy > 3 months

- The patient must have the following laboratory values in the 21 days prior to initiation of treatment (day 1, cycle 1):

1. Platelet count = 100 x 109/L and absolute neutrophil count of = 1.0 x 109/L. - Platelet transfusions to help patients meet eligibility criteria are not allowed.

2. Corrected serum calcium < 14 mg/dL.

3. Aspartate transaminase (AST) and alanine transaminase (ALT) = 2.5 x the upper limit of normal (ULN)

4. Total bilirubin within normal range

5. Calculated creatinine clearance > 30 mL/min

- Female patients who:

1. Are postmenopausal for at least 1 year before the screening visit, OR

2. Are surgically sterile, OR

3. If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 90 days after the last dose of study drug, AND

4. Must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, OR

5. Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception.)

- Male patients, even if surgically sterilized (ie, status post-vasectomy), must agree to one of the following:

1. Agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug, OR

2. Must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, OR 30 Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception.)

Exclusion Criteria:

- Patients not included in clinical trial GEM2012MENOS65

- Patients included in GEM2012MENOS65 who are not found to have a least minimal response after consolidation

- Patients included in GEM2012MENOS65 who were discontinued prematurely due to toxicity or disease progression

- Female patients who are lactating or have a positive serum pregnancy test during the screening period.

- Central nervous system involvement

- Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment.

- Systemic treatment, within 14 days before the first dose of MLN9708, with strong inhibitors of CYP1A2 (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of CYP3A (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort.

- Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol.

- Known GI disease or GI procedure that could interfere with the oral absorption or tolerance of MLN9708 including difficulty swallowing.

- Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.

- Peripheral neuropathy = grade 2 in the 21 days prior to inclusion.

- Known hypersensitivity to lenalidomide or to MLN9708, their analogues, or excipients in the various formulations of any agent.

- Patients who have had a myocardial infarction in the six months prior to inclusion in the clinical trial, or who are class III or IV according to the New York Heart Association (NYHA), heart failure unstable angina, uncontrolled ventricular arrhythmias or acute ischemia detected by electrocardiogram, or conduction disorders.

- Patients who are currently participating in another clinical trial or receiving any other investigational product.

- Seropositive for HVB, HVC or HIV.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
MLN9708

Lenalidomide

Dexamethasone


Locations

Country Name City State
Spain Complejo Hospitalario Universitario de Santiago A Coruña
Spain Hospital Txagorritxu Alava
Spain Hospital General de Albacete Albacete
Spain Hospital Del Vinalopo Alicante
Spain Hospital General Universitario de Alicante Alicante
Spain Hospital de Cabueñes Asturias
Spain Hospital Universitario Central de Asturias Asturias
Spain H.Universitari Germans Trias I Pujol de Badalona Barcelona
Spain Hospital Clinic Barcelona
Spain Hospital de La Santa Creu I Sant Pau Barcelona
Spain Hospital de Sabadell (Parc Taulí) Barcelona
Spain Hospital de Sant Joan de Déu Barcelona
Spain Hospital Del Mar Barcelona
Spain Hospital Universitari Mútua de Terrasa Barcelona
Spain Hospital Vall D'Hebron Barcelona
Spain Ico L'Hospitalet Barcelona
Spain Hospital Universitario de Burgos Burgos
Spain Complejo Hospitalario de Cáceres Cáceres
Spain Hospital de Especialidades de Jerez de La Frontera Cádiz
Spain Hospital Universitario Marqués de Valdecilla Cantabria
Spain Hospital General de Castellón Castello
Spain Hospital General de Ciudad Real Ciudad Real
Spain Hospital Universitari Dr. Josep Trueta de Girona Girona
Spain Hospital de Gran Canaria Doctor Negrín GRAN Canaria
Spain Hospital Universitario Virgen de Las Nieves Granada
Spain Hospital Universitario Guadalajara Guadalajara
Spain Hospital Universitario Donostia Guipúzcoa
Spain Hospital Son Llatzer Illes Balears
Spain Hospital Universitari Son Espases Illes Balears
Spain Hospital San Pedro La Rioja
Spain Hospital de León León
Spain Hospital Universitari Arnau de Vilanova de Lleida Lleida
Spain Centro Oncológico Md Anderson International España Madrid
Spain Fundación Jiménez Díaz-Ute Madrid
Spain Hm Universitario San Chinarro Madrid
Spain Hospital Clínico San Carlos Madrid
Spain Hospital de Fuenlabrada Madrid
Spain Hospital Del Tajo Madrid
Spain Hospital General Universitario Gregorio Marañón Madrid
Spain Hospital Infanta Leonor Madrid
Spain Hospital Infanta Sofía Madrid
Spain Hospital Ramón Y Cajal Madrid
Spain Hospital Severo Ochoa Madrid
Spain Hospital Universitario 12 de Octubre Madrid
Spain Hospital Universitario de La Princesa Madrid
Spain Hospital Universitario Fundación Alcorcón Madrid
Spain Hospital Universitario Infanta Cristina Madrid
Spain Hospital Universitario La Paz Madrid
Spain Hospital Universitario Puerta de Hierro Majadahonda Madrid
Spain Complejo Hospital Costa Del Sol (Ivcs) Malaga
Spain Hospital General Universitario Santa Lucia Murcia
Spain Hospital J.M. Morales Meseguer Murcia
Spain Hospital Universitario Virgen de La Arrixaca Murcia
Spain Clinica Universidad de Navarra Navarra
Spain Complejo Hospitalario de Navarra Navarra
Spain Complejo Hospitalario de Ourense Ourense
Spain Complejo Hospitalario de Pontevedra Pontevedra
Spain Hospital Universitario de Salamanca Salamanca
Spain Hospital Universitario de Canarias Santa Cruz de Tenerife
Spain Hospital General de Segovia Segovia
Spain Hospital Nuestra Señora de Valme Sevilla
Spain Hospital Virgen del Rocío Sevilla
Spain Hospital Santa Bárbara Soria
Spain Hospital Universitari Joan Xxiii de Tarragona Tarragona
Spain Complejo Hospitalario de Toledo Toledo
Spain Hospital Nuestra Señora Del Prado Toledo
Spain Hospital Clínico Universitario Valencia Valencia
Spain Hospital Universitario Dr. Peset Valencia
Spain Hospital Universitario La Fe Valencia
Spain HOSPITAL CLíNICO UNIVERSITARIO DE VALLADOLID Valladolid
Spain Hospital Universitario Del Rio Hortega Valladolid
Spain Hospital de Cruces Vizcaya
Spain Hospital Clínico Universitario Lozano Blesa Zaragoza
Spain Hospital Universitario Miguel Servet Zaragoza

Sponsors (3)

Lead Sponsor Collaborator
PETHEMA Foundation Celgene, Millennium Pharmaceuticals, Inc.

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-free survival Months to progression disease 5 years
Secondary Minimal Residual Disease (MRD) Number of patient with MRD and evaluation of its clinical significance 5 years
Secondary Overall survival Months of survival 6 years
See also
  Status Clinical Trial Phase
Recruiting NCT05027594 - Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05971056 - Providing Cancer Care Closer to Home for Patients With Multiple Myeloma N/A
Recruiting NCT05243797 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Phase 3
Active, not recruiting NCT04555551 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Completed NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03989414 - A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2
Active, not recruiting NCT03792763 - Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Phase 2
Withdrawn NCT03608501 - A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Phase 2
Recruiting NCT04537442 - Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1